MedTech Acquisition Corporation
MTAC
NASDAQ Capital Market11.34
USD
+1.78
- -
CIK
0001826667
ISIN
US58507N1054
CUSIP
58507N105
Return %
Stock
S&P500
1Y
14.31
26.84
3Y
7.79
77.03
5Y
7.79
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher C. Dewey
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 48 Maple Avenue Greenwich CT United States of America 06830
- IPO Date
- Feb 8, 2021
- CIK
- 0001826667
- Similar Companies
- Business
- MedTech Acquisition Corporation MedTech Acquisition Corporation (NASDAQ: MTAC) operates as a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the medical technology sector, including medical devices, diagnostics, digital health, and other health-related technologies in the United States and other developed countries; it offers no current products or services beyond its cash held in trust for deployment in a target acquisition. Founded in 2020 and headquartered at 48 Maple Avenue, Greenwich, Connecticut, the company went public via an initial public offering in December 2020, raising approximately $250 million in upsized proceeds. Its management team, led by Chairman Karim Karti, Chief Executive Officer Christopher C. Dewey, and Chief Financial Officer David J. Matlin, leverages extensive experience in healthcare, medical devices, and finance to identify and partner with innovative medtech targets. In recent developments, MedTech Acquisition Corporation entered into a definitive merger agreement with TriSalus Life Sciences, Inc. in November 2022 to take the oncology therapeutics developer public under the ticker TLSI, a transaction that closed on August 10, 2023, via reverse merger with significant redemptions but providing TriSalus over $60 million in cash including a $50 million convertible note; upon completion, MedTech Acquisition Corporation was renamed TriSalus Life Sciences, Inc., though MTAC remains listed with a recent stock price around $11.34 as of late 2025. Earlier, in August 2021, it announced but mutually terminated a business combination with Memic Innovative Surgery Ltd. in March 2022 due to market volatility, allowing pursuit of alternative targets like TriSalus focused on pressure-enabled drug delivery systems such as the FDA-cleared TriNav Infusion System and investigational immunotherapy SD-101 for liver and pancreatic tumors.
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal
Memic Going Public Via SPAC: What Investors Should Know About This Medical Device Company